All News NervGen Pharma Corp.

Equities

NGEN

CA64082X2032

Delayed Toronto S.E. Other stock markets 07:14:52 21/05/2024 pm IST			5-day change	1st Jan Change
2.19 ^CAD	-0.45%		+3.79%	-18.89%

17/04	NervGen Reports FY 2023 Net Loss of $0.38 Per Share, Provides Operations Update	MT
17/04	NervGen Pharma Corp. Reports Earnings Results for the Full Year Ended December 31, 2023	CI

All News

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

NervGen Pharma to Present Two Posters at the American Spinal Injury Association 51st Annual Scientific Meeting	20/05	AQ
NervGen Pharma to Present Two Posters at the American Spinal Injury Association 51st Annual Scientific Meeting	17/05	NE
NervGen Pharma Reports Q1 2024 Financial Results and Operational Updates	16/05	NE
NervGen Files Management Information Circular and Announces Board of Directors Transition	07/05	NE
NervGen Pharma : Notice of Meeting and Management Proxy Circular	07/05	PU
NervGen Engages Russo Partners LLC to Provide Public Relations Services	25/04	NE
NervGen Reports FY 2023 Net Loss of $0.38 Per Share, Provides Operations Update	17/04	MT
NervGen Pharma Reports 2023 Year-End Financial Results and Operational Updates	17/04	NE
NervGen Pharma Corp. Reports Earnings Results for the Full Year Ended December 31, 2023	17/04	CI
Non-Opioid Revolution: Beacons of Hope in Opioid Crisis and a $50 Million Spin-Off	09/04	AQ
NervGen Pharma Closes C$23 Million Bought Deal Financing	28/03	MT
NervGen Completes $23 Million Bought Deal Financing	28/03	NE
Canadian Investment Regulatory Organization Trade Resumption - NGEN	22/03	AQ
NervGen Pharma Raising C$20.1 Million in Bought-Deal Offering of Share Units	22/03	MT
NERVGEN ANNOUNCES $20 MILLION BOUGHT DEAL OFFERING	22/03	AQ
Canadian Investment Regulatory Organization Trading Halt - NGEN	22/03	AQ
NervGen Pharma Recognized as a Top 50 TSX Venture Exchange Company	21/02	NE
NervGen Pharma Grants Stock Options	21/02	NE
NervGen Pharma Corp. Plans to Initiate A New Study in Which Subjects Completes Open-Label Nvg-291	15/02	CI
NervGen Pharma on Track to Complete Enrollment, Deliver Data Readout in Phase 1b/2a Clinical Trial for NVG-291 in Spinal Cord Injury	15/02	NE

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

All News NervGen Pharma Corp.

Equities

NGEN

CA64082X2032

All News

Filters